Clinical Trials

The purpose of this research study is to understand the effects of changes in the capability of the heart on brain function so that we can better predict who will most benefit from cardio-resynchronization therapy (CRT) and how it may enhance brain health.

The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block (LBBB).

The purpose of this study is to assess the presence and severity of mechanical dyssynchrony in patients with congestive heart failure (CHF) when selecting to CRT in resting and after-exercise echocardiography by multiple echocardiographic techniques, and to evaluate association of exercise-induced mechanical dyssynchrony with acute response to CRT. 

The purpose of this study is to determine the long-term outcome of cardiac resynchronization therapy (CRT) recipients with congestive heart failure and any indications for CRT at Mayo Clinic.   

The purpose of this study is to determine the resuts of adjusting atrial-ventricular (AV) and interventricular (VV) timing delays on cardiac hemodynamics at rest and during exercise for patients who have a CRT (cardiac resynchronization therapy) device. Most current attempts to optimize CRT are done under resting conditions and patients report symptoms during mild daily exercise.

The purpose of this study is to determine the role of blood vessel tissue function in heart failure, and the effect of cardiac resynchronization therapy (CRT) on tissue and heart function.

The purpose of this study is to evaluate the safety and effectiveness of the WiSE-LV System for Cardiac Re-synchronization Therapy.

Congestive heart failure (CHF) affects nearly 5 million Americans and claims more than 300,000 lives annually. A primary pathophysiologic mechanism in this deadly syndrome is an abnormally enhanced sympathetic nervous system that results in profound peripheral vasoconstriction, attenuated cardiovascular reflexes, higher susceptibility to ventricular arrhythmias, and sudden cardiac death. The reduction in mortality and morbidity in CHF by pharmacologic neurohumoral antagonists such as beta-receptor inhibitor and angiotensin II-converting enzyme (ACE) inhibitor has taught us that regulation of the impaired neurohumoral axis is important for improving clinical outcome. In addition, an emerging nonpharmacologic approach, cardiac resynchronization therapy (CRT), has shown promise ...

The purpose of this study is to gather information to develop and validate a predictive tool for predicting the response to CRT therapy.

The purpose of this study is to evaluate the ability of the TYRX Absorbable Antibacterial Envelope to reduce major cardiovascular implantable electronic device infections through 12-months post-procedure following  generator replacement, upgrade, revision, or new CRT-D implant.

The aim of this study is to evaluate the relation of the acute pacing threshold (volts at ‘x’ pulse width) to the chronic pacing threshold of a pacemaker/ICD lead by studying the threshold during implantation at different pulse widths (eg. Twice of ‘x’, Three times of ‘x’).